iRBD向神经退行性突触核蛋白病早期转化的预测标志物
该研究在中国iRBD人群中随访5年,评估临床评估与DAT显像对神经退行性突触核蛋白病早期转化的预测价值。非运动症状问卷评分高、自主神经功能障碍问卷评分高及左侧纹状体/壳核DAT结合降低均与转化风险升高相关。
要点
- 非运动症状问卷评分高者转化风险升高(HR 3.11)。
- 自主神经功能障碍问卷评分高者转化风险升高(HR 4.46)。
- 左侧纹状体及壳核DAT结合降低与转化风险升高相关。
核心结论
- 自主神经功能障碍与DAT摄取降低可识别iRBD向神经退行性突触核蛋白病高转化风险患者。
主要发现
- 非运动症状问卷评分较高者转化风险更高(HR 3.11,95%CI 1.15-8.40,p=0.026)。
- 自主神经功能障碍问卷评分较高者转化风险更高(HR 4.46,95%CI 1.64-12.10,p=0.003)。
- 左侧纹状体99mTc-TRODAT-1结合降低者转化风险更高(HR 2.7,95%CI 1.02-7.14,p=0.046)。
- 左侧壳核99mTc-TRODAT-1结合降低者转化风险更高(HR 3.23,95%CI 1.16-8.33,p=0.024)。
临床怎么用
- 对iRBD患者可结合非运动症状问卷、自主神经功能障碍问卷及DAT-SPECT显像评估转化风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine the predictive value of clinical assessment and dopamine transporter (DAT) uptake for the early development of neurodegenerative synucleinopathy diseases from idiopathic REM sleep behavior disorder (iRBD) over 5 years in a Chinese population. METHODS: Forty-three patients with iRBD were administered clinical assessment tests, and 35 were examined by DAT-SPECT imaging during 2011. Cox proportional hazard and Kaplan-Meier analyses were used to evaluate the predictive value of the markers in a follow-up study over 5 years. RESULTS: Eighteen patients (41.9%) developed neurodegenerative synucleinopathy diseases after a median of 4.1 years of prospective follow-up (median interval of 10.5 years from the estimated onset of iRBD symptoms). Patients with higher scores on the Nonmotor Symptom Questionnaire (hazard ratio [HR] 3.11, 95% confidence interval [CI] 1.15-8.40, p = 0.026) and Scale for Outcomes in Parkinson Disease-Autonomic questionnaire (HR 4.46, 95% CI 1.64-12.10, p = 0.003) were more likely to develop neurodegenerative synucleinopathy diseases. Furthermore, the population with decreased 99mTc-TRODAT-1 binding in the left striatum (HR 2.7, 95% CI 1.02-7.14, p = 0.046) and putamen (HR 3.23, 95% CI 1.16-8.33, p = 0.024) had a relatively higher risk of developing neurodegenerative synucleinopathy diseases. CONCLUSIONS: Our findings elucidate the predictive value of autonomic dysfunction and DAT uptake in identifying patients with iRBD at a high risk of progressing into neurodegenerative synucleinopathy diseases and could form a basis for future disease-prevention trials.
引用
- Li Y, Kang W, Yang Q, et al. Predictive markers for early conversion of iRBD to neurodegenerative synucleinopathy diseases. Neurology. 2017. PMID: 28330956. doi:10.1212/WNL.0000000000003838
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。